Wolves have completed the £24m signing of Genk striker Tolu Arokodare.
The 6ft 6in Nigeria international has signed a four-year deal at Molineux.
Wolves are currently bottom of the Premier League having lost their opening three games.
Arokodare, who scored 21 goals in the Belgian Pro League to win the Golden Boot last season, will offer support in attack for Jorgen Strand Larsen.
The Norway forward was a target for Newcastle, but Wolves rejected bids of £50m and £55m for him last week.
Arokodare, 24, scored 41 goals in 113 appearances for Genk after joining from Latvian side Valmiera in 2023 and has one goal in four matches for Nigeria.
He moved to Valmiera from Nigeria in 2019, scoring 22 goals in 34 games.
Arokodare was loaned out to FC Koln in the Bundesliga before joining French side Amiens, spending two years on loan and scoring 21 times.
He has played five times for Genk this season, scoring once.
Apixaban 2.5 mg twice daily significantly reduced symptomatic venous thromboembolism (VTE) recurrence, with a low risk of major bleeding, in patients with provoked VTE and enduring risk factors, according to late-breaking research presented in a Hot Line session today at ESC Congress 2025 and simultaneously published in New England Journal of Medicine.
People can develop a blood clot that blocks a vein (VTE) because of short-term factors, such as surgery or injury, or as a result of a chronic medical condition, such as cancer.
Explaining the rationale of the HI-PRO trial, Principal Investigator, Doctor Gregory Piazza from Brigham and Women’s Hospital, Boston, USA, said: “Patients with acute VTE with transient provoking factors, such as surgery, trauma or immobility, typically receive short-term anticoagulation. However, the risk of VTE recurrence may remain high in certain patients with enduring risk factors, including those with obesity, chronic lung disease or autoimmune disorders. In such patients, the optimal duration of anticoagulation is uncertain. We designed the HI-PRO trial to assess the efficacy and safety of extended-duration apixaban 2.5 mg twice daily, compared with placebo, for the prevention of recurrence in patients with provoked VTE and at least one enduring risk factor.“
The double-blind, randomized controlled HI-PRO trial was conducted at Brigham and Women’s Hospital. Eligible patients had deep vein thrombosis (DVT) or pulmonary embolism (PE) following a major provoking factor (e.g. major surgery or major trauma), had completed at least 3 months of standard-dose anticoagulation and had at least one enduring risk factor (e.g. body mass index [BMI] ≥30 kg/m2, chronic lung disease or chronic inflammatory disease). Patients were randomized 1:1 to apixaban 2.5 mg twice daily or placebo for 12 months. The primary efficacy outcome was symptomatic recurrent VTE, a composite of DVT and/or PE at 12 months. The principal safety outcome was major bleeding according to the International Society on Thrombosis and Haemostasis definition.
In total, 600 patients underwent randomization. The mean age was 59.5 years and 57% were female. The most common provoking factors were surgery (33.5%), immobility (31.3%), trauma (19.2%) and acute medical illness (18.3%). The most common enduring risk factors were chronic inflammatory disorder (52.2%), BMI ≥30 kg/m2 (48.2%), atherosclerotic cardiovascular disease (29.3%) and chronic lung disease (22.3%).
Symptomatic recurrent VTE occurred in 1.3% of patients in the apixaban group compared with 10.0% in the placebo group, representing a significant 87% decrease (hazard ratio [HR] 0.13; 95% confidence interval [CI] 0.04 to 0.36; p<0.001). A secondary composite outcome of cardiovascular death, non-fatal myocardial infarction, stroke/transient ischemic attack or systemic embolism, major adverse limb event, and coronary or peripheral ischemia requiring revascularization occurred with a similarly low frequency with apixaban and placebo (0.7% vs. 1.0%, respectively; HR 0.67; 95% CI 0.11 to 3.98).
Major bleeding occurred in one patient (0.3%) who received apixaban and none who received placebo. Clinically relevant non-major bleeding was observed in 4.8% of patients in the apixaban group and 1.7% in the placebo group (HR 2.68; 95% CI 0.96 to 7.43; p=0.059). Death occurred in one patient in the apixaban group and three in the placebo group, with no deaths due to cardiovascular or hemorrhagic causes. Adverse events other than bleeding or death occurred in 2.0% of patients in both groups.
Low-intensity apixaban for 12 months effectively reduced symptomatic VTE recurrence with a low risk of major bleeding in patients with provoked VTE and enduring risk factors. Additional research is needed to identify which subgroups benefit most from extended anticoagulation.”
Doctor Gregory Piazza, Brigham and Women’s Hospital, Boston, USA
Allergic contact dermatitis (ACD) continues to be a significant occupational and consumer health issue, with new cases emerging from both industrial and everyday exposures. Two recent case studies, 1 involving a pipe relining worker sensitized to acrylates and another involving nickel exposure from a cosmetic applicator, demonstrate how ACD arises in unexpected contexts.1-2 Recent research on titanium allergy further broadens the conversation, underscoring that even metals once thought biologically inert may pose underrecognized risks.3 Together, these findings provide timely lessons as Labor Day draws attention to worker and consumer safety.
Case 1: Acrylate Allergy in Pipe Relining
A 56-year-old technician with over a decade of experience in pipe relining developed recurrent facial erythema, eyelid edema, and vesicle formation shortly after his company transitioned from epoxy-based to acrylate-based resins. Researchers stated patch testing confirmed sensitization to multiple acrylates and methacrylates, and to epoxy resin at higher concentrations. Despite personal protective equipment, contamination of gloves and clothing led to repeated facial exposure.1
The presentation initially suggested type I hypersensitivity, according to the study, but the delayed onset of symptoms and strong patch test responses confirmed ACD. Ultimately, the severity of his reactions required sick leave and cessation of work. This case highlights the diagnostic complexity of occupational dermatitis and the rising relevance of acrylate allergy in industrial settings, particularly as acrylate-based systems become more widely adopted.
Case 2: Nickel in Cosmetic Applicators
A 41-year-old woman developed eyelid dermatitis after using an eye cream packaged with a metal applicator. While the cream itself tested negative, patch testing confirmed sensitization to nickel, and repeated open application testing implicated the applicator tip as the source. This novel route of exposure underscores how cosmetic packaging, not just product formulation, can trigger ACD.2
The case emphasizes gaps in regulatory oversight: while the EU Nickel Directive restricts nickel release in jewelry and accessories, cosmetic packaging remains largely unregulated. As metal applicators and rollers gain popularity, researchers behind the case study suggested clinicians should consider packaging materials as potential hidden allergens.
Emerging Evidence: Titanium Allergy
Titanium has long been considered a safe and biocompatible metal, widely used in aerospace, automotive, and medical industries. Titanium dioxide (TiO₂), its most common form, serves as a physical UV filter in sunscreens and cosmetics, and titanium alloys are the standard material in orthopedic and dental implants due to their strength, corrosion resistance, and ability to integrate with bone. It is also marketed as “hypoallergenic” in jewelry for patients with nickel allergy.3
Traditionally, titanium was considered non-allergenic, as TiO₂ does not penetrate skin or gastrointestinal barriers. However, emerging research demonstrates that titanium ions and salts released from corrosion products can activate immune responses. A recent retrospective study from Tel Aviv Sourasky Medical Centre evaluated 255 patients patch tested with a metal series between 2012 and 2024. Titanium oxalate hydrate elicited positive reactions in 5% of patients, while titanium nitride did not. Most sensitized patients were women, often with co-sensitization to nickel, cobalt, or vanadium.
Clinical presentations included localized dermatitis on the hands or face, but researchers noted 2 patients developed generalized rashes after implant placement, including 1 case of bullous pemphigoid following hip replacement surgery. These findings suggest titanium-induced sensitization may play a role in implant failure and systemic skin disorders, although the diagnosis remains controversial due to variability in patch test reagents and interpretation.
Skin Safety Across Work and Life
Together, these cases and research findings illustrate the evolving nature of ACD in both occupational and consumer settings. For workers, acrylates represent a growing hazard in industries adopting new resin systems, with contamination risks persisting even with protective equipment. For consumers, nickel in cosmetic packaging demonstrates that allergen exposure extends beyond workplace environments, often in ways overlooked by existing regulations. The titanium data highlight the need to remain cautious about materials assumed safe, particularly as medical device use expands worldwide.
On Labor Day, when worker protections and occupational health come into focus, these examples remind clinicians and policymakers alike that skin safety is integral to overall safety. Comprehensive patch testing, including patient-specific materials, remains the diagnostic gold standard, though additional methods such as lymphocyte transformation assays may provide adjunctive value. At the regulatory level, stronger oversight of both industrial and consumer materials could help prevent emerging sources of sensitization.
Conclusion
ACD reflects the intersection of industrial progress, consumer trends, and clinical vigilance. The relining worker’s acrylate allergy, the consumer’s nickel exposure from a cosmetic applicator, and the expanding evidence on titanium sensitization all demonstrate the wide range of risks modern workers and consumers face. As industries evolve and new products enter the market, clinicians must remain alert to novel sources of allergen exposure. Labor Day offers an important reminder that protecting skin health—whether in the workplace or at home—is essential to safeguarding overall well-being.
References
Szumniak J, Dahlin J, Antelmi A. Occupational allergic contact dermatitis resembling angioedema induced by acrylates in a pipe relining worker. Contact Dermatitis. 2025. doi:10.1111/cod.70023
Sukakul T, Dahlin J, Svedman C. Eyelid allergic contact dermatitis caused by nickel from a surprising source: An illustrating case of illuminating eye care. Contact Dermatitis. 2025. doi:10.1111/cod.70009
Daniely D, Zemser-Werner V, Gilon-Omer R, Bar J, Slodownik D. Titanium: An unusual allergen With various presentations-A retrospective cohort study. Contact Dermatitis. Published online August 26, 2025. doi:10.1111/cod.70021
What does it mean for you to be a part of this World Cup squad?
It’s an honour, honestly. Everyone knows being part of a World Cup roster is something hard to get to. To be recognised and then to be able to come out and compete against all these world-class players is hard, so just being here is an honour and a blessing.
Aside from your own country, which country do you think has the best rugby fans?
Tonga!
Are there any jobs that you think you would be terrible at?
Anything that has to do with communication, a lot of times I’d be terrible at it.
Do you have any irrational fears?
Snakes. I think my mum passed that down to me.
What made you want to compete at rugby at this level?
Honestly, in Polynesian culture you’re not given many opportunities. It’s hard to get your name out there. I really wanted to put us on the map. So I hope I am able to do that.
If you could go on a holiday anywhere when you’re not playing rugby, where would you go?
Singapore is my dream destination. It’s always been a dream of mine. The world’s cleanest country and then one of my favourite movies, Crazy Rich Asians, is over there.
Tahlia Brody
If you could only speak in movie quotes for the rest of your life, which movie would you quote the most?
Star Wars. Empire Strikes Back is my favourite. A quote that makes me giggle a lot is the one from Attack of the Clones: “I don’t like the sand, it’s coarse and rough.”
If you could live anywhere in the world for a year, where would you choose?
Japan. I love the Japanese language, the Japanese culture. I have several friends that are in Japan. I practice a little bit of Japanese martial arts, so it would be really cool to go visit Okinawa, where the style originates from. I just had an amazing time when I was there previously.
You travel a lot for the sport is there any weird souvenirs that you’ve picked up?
When I was in Amsterdam I got one of those aprons that had the naked chest for my brother!
Do you have any random hobbies that you do outside of the sport?
I am a huge Star Wars nerd, anime nerd. I like drawing. I really enjoy baking.
If you could choose any personal mascot to represent you at the tournament, what would it be?
Peanut butter and jelly. Macaroni and cheese. Milk and cookies. Some pairings are just classic. I’m here to add one to your list. Nike and Lego. That’s right, the iconic fashion clothing and shoe brand is partnering up with your kid’s favorite toy brand, and it’s one for the record books. The Nike x Lego collab is available now, launching on Monday, Sep. 1.
Whether you are obsessed with Legos (or have a kid obsessed with them), or you love a stylish collab, this collection works for you. You can choose from Nike and basketball-themed Lego sets, or Lego-styled clothing options including jackets, shoes and even a backpack. The collection is perfect for the back-to-school season, or getting a head start on their holiday wish list.
Here’s a look at the Nike and Lego collab, available now:
Shop the Nike x Lego collab
Shop the Nike x Lego collab
Nike Dunk Trickshot x LEGO® Set
NIKE LABOR DAY DEAL: The popular Nike Pegasus 41 SE running shoes are 29% off for Labor Day
Nike Dunk x LEGO® Set
Nike Dunk Low x LEGO® Collection
WICKED LEGO SETS: New ‘Wicked: For Good’ Lego sets are gonna be Popular. Preorder yours today
Nike x LEGO® Collection Heritage Backpack
Nike x LEGO® Collection Basketball Jacket
What is a Nike membership?
A Nike membership is your all-access pass to the world of Nike. Whether you’re shopping for sneakers, a cult-favorite workout legging, or just love a good deal on a premium brand, a Nike membership works for you. It’s free to join and unlocks a number of perks from exclusive style drops to personalized workouts.
Create a Nike membership account
How to create a Nike membership account
Signing up for a Nike membership account is simple and fast. You can join via the Nike website. All you need is your email, name and a password. Once you’re in, you’re good to go and can start taking advantage of membership perks.
What benefits does a Nike membership offer?
A Nike membership comes with a long list of perks. Here are some of them:
Special offers and birthday rewards
Free shipping on every order of $50 or more
60-day risk-free wear test that accepts returns even if you’ve worn the item
Exclusive member-only products you won’t find anywhere else
Early access to new launches, including collabs and limited releases
Nike app benefits include personalized workouts and training plans
Solid-state drive (SSD) prices per gigabyte (GB) have headed sharply upwards over the past two quarters.
Meanwhile, on the spinning disk front, SAS hard disk drive (HDD) prices increased in price and SATA stayed stable, to leave an increased gap between the two.
SSD prices had been predicted to increase as manufacturers slowed production in an ongoing effort to raise prices that had dropped away during a long period of surplus production.
Meanwhile, SAS drive prices also increased while SATA spinning disk price per gigabyte stayed steady. The net effect is for the SAS side of the scissors to move upwards and away from SATA.
Possible causes include a similar situation of oversupply that is now working its way out as manufacturers cut back on production. Also, SAS is the more performant of the two HDD types and may be in greater demand for large-scale data storage for artificial intelligence (AI).
During the past two quarters, Flash drive prices (MLC, TLC and QLC) increased from $0.079/GB to $0.086/GB, an 8.8% increase. If we take QLC out of the equation – because of a low sample size in the data (see below) – that rises to $0.093/GB and a 17.7% increase. The reality probably lies between the two.
Also, during the past two quarters, SAS spinning disk prices per gigabyte rose from $0.049 to $0.051, an increase of just over 4%. Across the year, however, the increase has been from $0.041 to $0.051, nearer 25%.
SATA drive prices – the less performant of the two protocols – have remained steady. SATA price per gigabyte six months ago was $0.035 and is now $0.036.
The reason for the big increase in SAS prices also lies in a recent history of overproduction being throttled back to help the price by manufacturers, and likely higher demand for performance-hungry AI applications.
It must be noted that HDD is still the dominant medium in data storage in 2025.
Flash prices hit a ceiling in late 2023 and early months of 2024 when manufacturers slowed production to try to raise prices and boost profitability. SSD prices per gigabyte reached an average of $0.095 in April 2024, which was a rise of 26.67% from autumn 2023.
At the time, many thought SSD prices would achieve even greater highs in 2024, but while production increased, customer demand did not, and prices decreased.
These figures are from exclusive analysis by Computer Weekly that gathers drive prices aggregated by Diskprices.com (see graph) every week from Amazon.com. Since March 2023, more than 84,000 drive prices and specs have been gathered, with averages calculated every week for TLC, QLC and MLC/unspecified flash drives, as well as SAS and SATA spinning disk.
Disk prices from April 2023 to September 2025
Diskprices.com aggregates new drive prices that it takes from Amazon.com, with more than 700 disk prices and specifications processed every week. Data is then filtered by flash and spinning disk type, and the average price per gigabyte calculated.
The analysis is based on Amazon.com prices, which are mostly aimed at consumers and SME customers, and therefore lacks, for example, much representation of QLC flash, which is aimed at use cases that require predominantly sequential access and offer greater density.
Having said that, the volume of data gathered helps to show trends in drive pricing. We use it here as a proxy for drive prices because of the absence of price data from enterprise drive and storage array makers.
Price per gigabyte is a major consideration for customers, but total cost of ownership over a drive’s lifecycle is also important, with purchase cost, energy usage and maintenance costs key among them.
Data gathered covers drives that range in capacity from less than 1TB (terabyte) up to 30TB for HDDs and up to 12TB for SSDs.
SSD costs more per drive to buy than spinning disk, but maintenance costs are often lower. Cloud storage provider Backblaze publishes reliability figures for the 300,000-plus drives in its estate. It found its SSD annual failure rate (AFR) to be 0.9% in mid-2023. There have been no AFR stats for SSDs from Backblaze since, but for HDDs, the figure for 2024, reported in February 2025, was 1.57%.
Investors resorted to robust buying of attractive shares at the Pakistan Stock Exchange (PSX) on Monday as the benchmark KSE-100 index soared around 1,350 points and closed just a few points short of the 150,000 mark.
The market exhibited a sustained momentum throughout the session, during which the index climbed to the intra-day peak of 150,066 points. By the end of trading, the KSE-100 settled at 149,971.12, up a handsome 1,353.34 points, or 0.91%.
The rally reflects optimism among market participants, triggered by positive cues from key sectors such as cement and exploration & production. Revealing inflation statistics, the Pakistan Bureau of Statistics (PBS) reported that the Consumer Price Index (CPI) fell from 4.1% in July to 3% in August, driven by lower food and electricity prices.
Arif Habib Limited (AHL) commented in its report that a strong follow-through rally, continuing Friday’s sharp momentum, propelled the KSE-100 index back towards the 150,000 level.
Some 67 shares rose while 32 fell, where the major positive contribution came from Lucky Cement (+4.24%), Oil and Gas Development Company (+2.27%) and Fauji Cement (+7.39%). On the flip side, Fauji Fertiliser Company (-0.63%), Systems Limited (-1.77%) and Pakgen Power (-6.33%) were the biggest index drags, said AHL.
Among corporate news, Sazgar Engineering released its FY25 results, where the company declared earnings per share of Rs131.29, up 106% year-on-year (YoY), and dividend per share of Rs52. For 4QFY25, the EPS remained steady at Rs57.60 while the company announced dividend per share of Rs20.
AHL pointed out that the monthly CPI-based inflation eased in August, though torrential monsoon rains disrupted supply chains and pushed up prices. The CPI recorded a rise of 3% YoY compared to 4.1% in July. The brokerage anticipated that gains in the KSE-100 index would continue towards the weekly draw at 151.2k.
Overall trading volumes decreased to 1.2 billion shares compared with previous session’s tally of 1.3 billion. Traded value stood at Rs48.8 billion. Shares of 480 companies were traded. Of these, 272 rose, 175 fell and 33 remained unchanged. The Bank of Punjab was the volume leader with trading in 97.7 million shares, gaining Rs1.51 to close at Rs16.58.
At the European Society of Cardiology (ESC) Congress 2025, findings from a post-hoc analysis of the SURMOUNT-5 trial (NCT05822830) were presented, comparing tirzepatide to semaglutide for their impact on cardiovascular disease (CVD) risk in adults with obesity but without type 2 diabetes (T2D) or established CVD. Given that reducing CVD risk is a primary objective in obesity management, the analysis aimed to estimate ten-year CVD risk reduction and project preventable primary CVD events across the US and France, Germany, Italy, Spain, and the UK (5EU).
The study utilised a BMI-based Framingham CVD risk score to evaluate ten-year CVD risk among participants who completed 72 weeks of treatment. Subgroup analyses were performed by sex, race, and baseline BMI. The projected impact of tirzepatide and semaglutide on ten-year CV events prevented was calculated by multiplying the treatment-eligible population across countries included in the study by the ten-year risk reduction estimated for each patient treated.
In results presented at the ESC conference by Professor Mamas Mamas, Keele Cardiovascular Research Group, Keele University, Stoke-on-Trent, UK, while both GLP-1 receptor agonists were associated with a reduction in ten-year CVD risk, tirzepatide achieved a significantly greater reduction in CVD risk than semaglutide (2.4% versus 1.4%, respectively; p<0.001). This trend was identified as early as 12 weeks into the study, where a clear separation can be noticed between the tirzepatide and semaglutide groups. By week 72, tirzepatide MTD (10mg or 15mg) led to a 23.7% reduction in predicted ten-year CVD risk, compared to 13.6% with semaglutide MTD (1.7mg or 2.4mg) (p<0.001). Tirzepatide consistently outperformed semaglutide across individual risk factors—including BMI, systolic blood pressure, LDL cholesterol, HbA1c, and hypertension—and demonstrated consistent benefits across demographic and BMI subgroups.
Projections based on the treatment-eligible populations suggest that tirzepatide could prevent over 3.1 million CVD events across the US and 5EU combined over ten years. In contrast, semaglutide was estimated to prevent 1.8 million across all six countries. These findings underscore tirzepatide’s potential superiority over semaglutide in primary CVD prevention among individuals with obesity without T2D, aligning with emerging real-world evidence on its cardiometabolic benefits.
Key opinion leaders (KOLs) interviewed by GlobalData expressed that “you [have] got to make sure that you show that you are not just improving the weight of the patients, but you are improving the health of the patients [too]. So, you do have to look at the diabetes, and hypertension, and lipids…and you do have to look at the cardiovascular disease outcome [too]”.
According to GlobalData’s Pharma Intelligence Center, there are 35 Phase III candidates, 94 Phase II candidates, and 111 Phase I candidates for obesity globally. As for CVD, there are 96 Phase III candidates, 201 Phase II candidates, and 206 Phase I candidates worldwide.
Celebrating 50 years of racing in 2025, Van Amersfoort Racing have enjoyed plenty of highs over the course of their history, endured tougher spells but as eponymous team owner Frits Van Amersfoort told us, the passion for racing remains undimmed.
Reflecting on his and his team’s journey from upstarts in the 1980s to competing on Formula 1 race weekends and celebrating plenty of famous drivers in between, Van Amersfoort says that while things have changed a lot in racing since he started, some things never will.
“It’s a question that I’ve been asked often over the years,” he reflected after being asked how things have evolved from where VAR started out. “It sounds weird, but it feels like yesterday that we got started. Of course, the racing world has changed a lot over the years, but the thrill of racing feels the same.
“It started out with me building up our stock of equipment, then buying a small transporter, organising a small awning and I was pretty proud of it. It only had one car in it, but that’s how it started.
“I’m happy to keep the team alive for 50 years! That was probably the biggest hurdle. It’s not easy all of the time. We’ve had challenging years but since being back in F2 and F3, things have gone well, and I’m proud to be here.
Frits Van Amersfoort continues to oversee his team in multiple championships 50 years on from starting out
“I think the last two decades especially things have changed. I remember even 10 years ago racing wasn’t the same as it is today. Look at things now, every team is big, they run almost every series they can, and they employ a lot of people. That’s how racing is now – the racing level has increased an incredible amount on and off the track.”
Van Amersfoort were not a part of the inaugural FIA Formula 2 or Formula 3 campaigns back in 2017 and 2019 respectively. But since joining both Championships, the team has achieved success with several race victories, pole positions and points-scoring results.
The team owner says that the challenge both pose is a huge source of motivation even after all of the other categories and championships the team has participated in.
“F2 and F3 are still a big challenge, especially F2. We keep learning every day and maybe in all the years we’ve been a team, it’s the best thing we’ve done. The years we had with Max were great, but in this Championship, everything that’s involved and that goes into it, it’s a different league.
“The driver can’t do it alone without the team, and the team can’t do it without the driver. It’s different to how it was in the past. That’s why it’s so massively interesting. The challenge for the team year after year, and the learnings, it takes so much to compete at this level.”
Van Amersfoort says his experience continues to be valued as the team evolves
Van Amersfoort has seen almost everything over the course of his tenure overseeing the rise of the Dutch outfit from upstarts to international racing team.
He says the lessons over the years are as important as ever, with the increased level of professionalism and eye for detail compared to when the team first started out.
He also noted how his experiences when VAR was a smaller operation still count for a lot, with the interaction between team personnel always critical to any success on the track.
“Maybe it’s good that the old man is still there! Now with 50 years of experience, everyone can still learn things and welcome advice. I’ve learned over those years, even with all the money involved in racing nowadays, there’s still the social side.
“I’m still looking at the team nowadays and I want to make sure everyone is able to work at their best. Because if they’re not, I feel like it’s an attack almost – I feel responsible.
“Everyone in the team, whatever they’re doing, I’ve done. Whether it’s a tyre guy, sweeping the floors at the factory, being a team manager, engineer, driving the truck, so I understand you. I understand what you need, your feelings and understand you, so I can help.
Through all the ups and downs, Van Amersfoort remains a racing fanatic
“It’s sport, it’s people. To keep the group together and motivated, I think I can still play a role in that. Now I don’t visit all the races in a season anymore, it’s time to relax a little bit more, but I’m more nervous watching on the television than at the circuit!”
Asked to pick out his favourite moments, Van Amersfoort took his time to look back on his experiences and top moments from over the years, and reflected on what the next half century might hold for VAR.
“I recently went to a friend’s birthday celebration, and he handed me an envelope of black and white pictures, and they were of me somewhere on the way to Zandvoort back in 1980 fettling with a Formula Ford car. It reminded me of how it all began.
“It’s very hard to say what has been the best moment over the 50 years. Of course you have the big names. We had the opportunity to sign Max for 2014, and the rest is history. Then we continued that with Charles afterwards too.
“We’ve won in FRECA, F3, F2 and more. Over the years, we’ve found some good people, Rob Niessink, my partner in crime since 1988. I could show you my phone and you’ll see Rob’s number is saved above my wife! And his is the same too.
“The next 50 years – I mean racing will change a lot by then as well like it has done over the years, but the passion will be there as always.”
